Bio-Rad Laboratories, Inc.
Essential Information
Financial Summary (TTM)
Fiscal Year: January - December
Revenue
Net Income
Free Cash Flow
Shares Outstanding
EPS
ROIC
Dividend Per Share
Debt/FCF
In-Depth Analysis of Bio-Rad Laboratories, Inc. (BIO)
Bio-Rad Laboratories, Inc. (BIO), listed on the NYSE, has a market capitalization of $7.78B. As of May 18, 2026, the stock is trading at $279.70 per share@else an unavailable price , offering investors a clear view of its current market value. Bio-Rad Laboratories, Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 44.82, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Bio-Rad Laboratories, Inc. also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Bio-Rad Laboratories, Inc. (BIO) may be overvalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Bio-Rad Laboratories, Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Bio-Rad Laboratories, Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Bio-Rad Laboratories, Inc. is 20.73, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Bio-Rad Laboratories, Inc. (BIO) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Frequently Asked Questions about Bio-Rad Laboratories, Inc. (BIO)
Is Bio-Rad Laboratories, Inc. a good stock to buy?
Whether Bio-Rad Laboratories, Inc. (BIO) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be overvalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
What is the fair value of Bio-Rad Laboratories, Inc.?
The fair value of Bio-Rad Laboratories, Inc. (BIO) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
What is Bio-Rad Laboratories, Inc.'s SS Score?
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Bio-Rad Laboratories, Inc.. To access the full SS Score, consider upgrading your subscription.
How does Bio-Rad Laboratories, Inc. compare to other stocks in the industry sector?
Bio-Rad Laboratories, Inc. is a significant player in the industry sector, with a market capitalization of $7.78B and a competitive P/E ratio of 44.82. Investors should compare these metrics with industry peers to gauge whether Bio-Rad Laboratories, Inc. is outperforming or underperforming within its sector.
News about Bio-Rad Laboratories, Inc. (BIO)
Activist Elliott Takes Major Stake in Bio-Rad — Can It Boost BIO Stock Price?
Activist investor Elliott Investment Management has reportedly built a sizable stake in Bio-Rad Laboratories ($BIO). According to the Wall Street Journal, Elliott is aiming to push management to impro...
Elliott builds big stake in life-science tools supplier Bio-Rad Labs, WSJ reports
Activist investor Elliott Investment Management has built a sizeable stake in U.S. diagnostics supplier Bio-Rad Laboratories , and plans to push the company to boost its underperforming stock price,...
Activist investor Elliot builds big stake in Bio-Rad, WSJ says
Activist investor Elliot Investment Management has built a big stake in Bio-Rad (BIO)e Laboratories, with plans to push the company to boost its underperforming stock price, Lauren Thomas of The…
Activist Elliott Builds Big Stake in Life-Science Tools Supplier Bio-Rad
Elliott also has a stake in German lab-equipment supplier Sartorius, where Bio-Rad is also an investor.
Bio-Rad resumed with an Outperform at RBC Capital
RBC Capital resumed coverage of Bio-Rad (BIO) with an Outperform rating and $320 price target The company’s sales growth should recover in 2027 following “idiosyncratic product headwinds” in 2026, the...
Bio-Rad to Participate in Upcoming Investor Conferences
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company will p...
Bio-Rad price target lowered to $290 from $320 at Wells Fargo
Wells Fargo lowered the firm’s price target on Bio-Rad (BIO) to $290 from $320 and keeps an Equal Weight rating on the shares. The firm notes Q1 missed on organic…
Bio-Rad reports Q1 EPS $1.89, consensus $1.99
Reports Q1 revenue $592.1M, consensus $588.86M. Norman Schwartz, Bio-Rad’s (BIO) Chairman and CEO, stated: “Our first-quarter results reflected our resolve in navigating a dynamic environment. Despite...
Bio-Rad Reports First-Quarter 2026 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t...
Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t...
Bio-Rad downgraded to Neutral from Buy at Citi
Citi analyst Patrick Donnelly downgraded Bio-Rad (BIO) to Neutral from Buy with a price target of $300, down from $375. The firm does not see a recovery path for the…
Bio-Rad downgraded to Neutral from Buy at Citi
Citi analyst Patrick Donnelly downgraded Bio-Rad (BIO) to Neutral from Buy with a $300 price target
Bio-Rad price target lowered to $320 from $340 at Wells Fargo
Wells Fargo analyst Brandon Couillard lowered the firm’s price target on Bio-Rad (BIO) to $320 from $340 and keeps an Equal Weight rating on the shares. The firm contends that…
Bio-Rad price target lowered to $335 from $350 at UBS
UBS lowered the firm’s price target on Bio-Rad (BIO) to $335 from $350 and keeps a Buy rating on the shares. While there were some bright spots, margins were “messy,”…
Bio-Rad reports Q4 adjusted EPS $2.51, consensus $2.70
Reports Q4 revenue $693.2M, consensus $687.71M. Norman Schwartz, Bio-Rad’s (BIO) Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on a...
Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t...
Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t...
Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chie...
3 Stocks Flashing ‘Buy’ Alerts for Investors on Technical Charts
Amid market volatility, technical analysis can help investors identify compelling stock opportunities. Using TipRanks’ Technical Analysis Screener, we’ve highlighted three stocks, Wintrust Financial (...
Bio-Rad price target raised to $375 from $350 at Citi
Citi raised the firm’s price target on Bio-Rad (BIO) to $375 from $350 and keeps a Buy rating on the shares. The firm cites higher peer multiples for the target…
Bio-Rad price target raised to $340 from $265 at Wells Fargo
Wells Fargo raised the firm’s price target on Bio-Rad (BIO) to $340 from $265 and keeps an Equal Weight rating on the shares. The firm says shares of Bio-Rad should…
Analysis Results
Parameters
Cash Flow Projections
Analysts Estimates
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2026 | 315.85M | Analyst x2 | |
| 2027 | 314.75M | -0.35% | Analyst x2 |
| 2028 | 325.90M | 3.54% | Analyst x1 |
| 2029 | 354.30M | 8.71% | Analyst x1 |
| 2030 | 383.90M | 8.35% | Analyst x1 |
| 2031 | 400.74M | 4.39% | Est @4.4% |
| 2032 | 416.25M | 3.87% | Est @3.9% |
| 2033 | 430.83M | 3.50% | Est @3.5% |
| 2034 | 443.89M | 3.03% | Est @3.0% |
| 2035 | 456.60M | 2.86% | Est @2.9% |
DCF Calculations
Complete Results
Present Value of Future FCFs
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2024A | 289.60M | 1.00 | 289.60M |
| 2025A | 374.60M | 1.00 | 374.60M |
| 2026E | 315.85M | 1.09 | 290.52M |
| 2027E | 314.75M | 1.18 | 266.30M |
| 2028E | 325.90M | 1.28 | 253.62M |
| 2029E | 354.30M | 1.40 | 253.61M |
| 2030E | 383.90M | 1.52 | 252.76M |
| 2031E | 400.74M | 1.65 | 242.70M |
| 2032E | 416.25M | 1.80 | 231.87M |
| 2033E | 430.83M | 1.95 | 220.75M |
| 2034E | 443.89M | 2.12 | 209.20M |
| 2035E | 456.60M | 2.31 | 197.94M |
| Terminal | 7.53B | 2.31 | 3.26B |